The guidelines now note that acute myeloid leukemia should be treated based on regimens that have been established in clinical trials, and they emphasize the importance of using the regimens consistently and not mixing induction from one with consolidation from another.

The guidelines also now list umbilical cord blood as an alternative source for patients with acute myeloid leukemia who are candidates for allogeneic stem cell transplant but do not have an appropriate sibling or unrelated donor available.